Table 1 Characterization of non-modified aSyn antibodies using recombinant synuclein proteins and peptides.

From: Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases

Antibody

Epitope

Species reactivity

bSyn detection

gSyn detection

Other amyloidogenic protein reactivity

Neighboring PTM sensitivity

Conformational selectivity

WB

DB

LASH-EGT403

1–5

hu, mus

+

+

–

–

m/o/f

m/o/f

5B10-A12

1–10

hu, mus

–

–

–

M5

m/o/f

m/o/f

LASH-EGTNter

1–20

hu, mus

+

–

–

–

m/o/f

m/o/f

LASH-BL 34–45

34–45

hu, mus

+

–

–

Y39

m/f

m/o/f

LASH-BL 80–96

80–96

hu, mus

–

–

–

–

m/o/f

m/o/f

BD SYN-1

91–99

hu, mus

–

–

–

–

m/o/f

m/o/f

BL 4B12

103–108

hu

–

–

–

–

m/o/f

m/o/f

2F10-E12

110–115

hu, mus

–

–

–

–

m/o/f

m/o/f

AB LB509

115–122

hu

–

–

–

P120-Y125

m/o/f

m/o/f

7H10-E12

115–125

hu

–

–

–

pY125

m/o/f

m/o/f

LASH-BL 117–122

117–122

hu

–

–

–

P120-Y125

m/o/f

m/o/f

LASH-BL A15127A

120–122

hu

–

–

–

–

m/o/f

m/o/f

4E9-G10

120–125

hu

–

–

–

pY125

m/o/f

m/o/f

1F10-B12

121–125

hu

–

–

–

–

m/o/f

m/o/f

4E9-C12

121–132

hu

–

–

–

pY125

m/o/f

m/o/f

2C4-B12

123–125

hu

–

–

–

pY125

m/o/f

m/o/f

6B2-D12

126–132

hu, mus

–

–

+/TDP-43

pS129

m/o/f

m/o/f

AB 134–138

134–138

hu, mus

+

–

–

D135

m/o/f

m/o/f

  1.  = truncation, aSyn alpha-synuclein, bSyn beta-synuclein, DB dot blot, f fibril, gSyn gamma-synuclein, hu human, m monomer, mus mouse, o oligomer, PTM post-translational modification, TDP-43 transactive response DNA-binding protein 43 kDa, WB Western blot.